Upcoming trial readouts

600 upcoming events · verified as of 2026-11-04 · soonest first.

All · Readouts · AdComm · Recent approvals

DateEventCompanyDrugOfficial source & verification
2026-11-05
in 1d
ESTIMATED
READOUT
Pediatric Long-Term Follow-up and Rollover Study
Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma
NVS NOVARTIS AG dabrafenib, trametinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-05
in 1d
ESTIMATED
READOUT
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig
Phase 2 · B-Cell Malignancies
INCY INCYTE CORP Parsaclisib, parsaclisib + itacitinib, p ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-05
in 1d
ESTIMATED
READOUT
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metast
Phase 1/2 · Prostate Cancer
AZN ASTRAZENECA PLC AZD9750, AZD5305 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-09
in 5d
ESTIMATED
READOUT
A Platform Study of Novel Immunotherapy Combinations in Participants With Previo
Phase 2 · Lung Cancer, Non-Small Cell
GlaxoSmithKline Pembrolizumab, Dostarlimab, Belrestotug, ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-11
in 7d
ESTIMATED
READOUT
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast
Phase 2 · Cervical Cancer, HPV-Related Carcinoma
PGEN PRECIGEN, INC. PRGN-2009 plus Pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-12
in 8d
ESTIMATED
READOUT
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop
Phase 2 · Atopic Dermatitis
PFE PFIZER INC PF-07275315, PF-07264660 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-13
in 9d
ESTIMATED
READOUT
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi
Phase 1/2 · Advanced Solid Tumors
REGN REGENERON PHARMACEUTICALS, I REGN7075, Cemiplimab, Platinum-based dou ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-13
in 9d
ESTIMATED
READOUT
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar
Phase 3 · Breast Cancer
Hoffmann-La Roche Inavolisib, Fulvestrant, Alpelisib, Bupr ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-13
in 9d
ESTIMATED
READOUT
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i
Phase 2 · Overweight or Obesity
REGN REGENERON PHARMACEUTICALS, I Olatorepatide ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-14
in 10d
ESTIMATED
READOUT
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Di
Phase 3 · Type 2 Diabetes Mellitus (T2DM)
BrightGene Bio-Medical Technology Drug: 5 mg BGM0504 Administered SC, Drug ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-14
in 10d
ESTIMATED
READOUT
A Study of BGM0504 in Participants With Type 2 Diabetes
Phase 3 · Type 2 Diabetes Mellitus (T2DM)
BrightGene Bio-Medical Technology Drug: 5 mg BGM0504 Administered SC, Drug ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-15
in 11d
ESTIMATED
READOUT
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis
Primus Pharmaceuticals Metaxalone 640 mg Oral Tablet ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-15
in 11d
ESTIMATED
READOUT
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla
Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension
PolyActiva Pty Ltd PA5108 Ocular Implant low dose, PA5108 O ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-16
in 12d
ESTIMATED
READOUT
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener
Phase 2/3 · Generalized Myasthenia Gravis
UCB Biopharma SRL Zilucoplan ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-17
in 13d
ESTIMATED
READOUT
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer
AZN ASTRAZENECA PLC AZD0901, 5-Fluorouracil, Leucovorin, l-l ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-17
in 13d
ESTIMATED
READOUT
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo
Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic
Swedish Orphan Biovitrum Efanesoctocog alfa ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-18
in 14d
ESTIMATED
READOUT
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym
Phase 2/3 · Small Cell Lung Cancer
Han Xu, M.D., Ph.D., FAPCR, Medica ETOPOSIDE - Usual, ETOPOSIDE - Study ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-18
in 14d
ESTIMATED
READOUT
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl
Phase 2/3 · Prostate Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponso Abiraterone - Usual, Abiraterone - Study ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-18
in 14d
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac
Phase 3 · Sjögren's Syndrome
BMY BRISTOL MYERS SQUIBB CO Deucravacitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-18
in 14d
ESTIMATED
READOUT
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymo
Phase 2/3 · ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Medicine Invention Design, Inc ALECENSA - alectinib hydrochloride capsu ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-18
in 14d
ESTIMATED
READOUT
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular D
Phase 2 · Duchenne Muscular Dystrophy
Hoffmann-La Roche Satralizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-18
in 14d
ESTIMATED
READOUT
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
ToLymph Inc. SMS001 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-19
in 15d
ESTIMATED
READOUT
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Par
Phase 4 · Severe Hemophilia A, Moderate Hemophilia A
Hoffmann-La Roche Emicizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-19
in 15d
ESTIMATED
READOUT
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participant
Phase 2 · Alzheimer's Disease
Hoffmann-La Roche RO7269162 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-19
in 15d
ESTIMATED
READOUT
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatiti
Phase 2 · Dermatitis, Atopic
Janssen Research & Development, LL JNJ-95597528 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-20
in 16d
ESTIMATED
READOUT
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With
Phase 3 · Endometrial Neoplasms
Merck Sharp & Dohme LLC Pembrolizumab, Carboplatin, Paclitaxel, ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-20
in 16d
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant
Phase 2 · Moderate to Severe Asthma
INCY INCYTE CORP povorcitinib, ICS-LABA ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-20
in 16d
ESTIMATED
READOUT
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-admi
Phase 2 · Obesity
SKYE Skye Bioscience, Inc. Nimacimab injection, Nimacimab placebo i ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-23
in 19d
ESTIMATED
READOUT
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) V
Phase 2 · Neoplasms, Colon
GlaxoSmithKline Dostarlimab, CAPEOX ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-23
in 19d
ESTIMATED
READOUT
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to He
Phase 3 · Chickenpox
GlaxoSmithKline Investigational varicella vaccine, Marke ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-24
in 20d
ESTIMATED
READOUT
Avelumab Program Rollover Study
Phase 3 · Solid Tumors
EMD Serono Research & Development Avelumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-24
in 20d
ESTIMATED
READOUT
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/2 · Metastatic Prostate Cancer
AZN ASTRAZENECA PLC AZD0754, AZD2287 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-24
in 20d
ESTIMATED
READOUT
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer
Phase 3 · Alzheimer Disease
Karuna Therapeutics, Inc., a Brist KarXT ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-24
in 20d
ESTIMATED
READOUT
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart F
Phase 2 · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
TECX Tectonic Therapeutic, Inc. TX000045- Dose A, TX000045- Dose B ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-26
in 22d
ESTIMATED
READOUT
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus
Phase 3 · Neoplasms
Tesaro, Inc. Dostarlimab, Carboplatin, Paclitaxel, Ni ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-26
in 22d
ESTIMATED
READOUT
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and
Phase 4 · COVID-19
SNY Sanofi Omicron Subvariant-Based SARS-CoV-2 Reco ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-28
in 24d
ESTIMATED
READOUT
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's
Phase 2 · Parkinson's Disease (PD)
TrueBinding, Inc. TB006 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-28
in 24d
ESTIMATED
READOUT
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P
Phase 3 · Yellow Fever Immunization
SNY Sanofi Yellow fever vaccine (live), Yellow feve ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-29
in 25d
ESTIMATED
READOUT
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f
Phase 3 · Menstrual Migraine
PFE PFIZER INC Rimegepant, Rimegepant ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutat
Phase 1/2 · Glioblastoma Multiforme
NTHI NEONC TECHNOLOGIES HOLDINGS, Perillyl alcohol ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-L
Phase 3 · Cancer
Hoffmann-La Roche Atezolizumab, Bevacizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
Phase 1/2 · Duchenne Muscular Dystrophy
SLDB Solid Biosciences Inc. SGT-001 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety
Phase 1/2 · Multiple Myeloma
Celgene CC-92480, Bortezomib, Dexamethasone, Dar ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable
Phase 2 · Non-small Cell Lung Cancer
Genentech, Inc. Alectinib, Entrectinib, Vemurafenib, Cob ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MT
Phase 1/2 · Advanced MTAP-null Solid Tumors
AMGN AMGEN INC Anvumetostat, Docetaxel, Comparator Anvu ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage D
Phase 1/2 · Glycogen Storage Disease
ModernaTX, Inc. mRNA-3745 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Pediatric Patients Aged 4 to 11 Years With APDS
Phase 3 · APDS
Pharming Technologies B.V. Leniolisib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte A
Phase 3 · Leukocyte Adhesion Deficiency
AUG Therapeutics AVTX-803 (L-Fucose) ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Phase 1/2 · Metastatic Castration-resistant Prostate Cancer
OncoC4, Inc. ONC-392 low, ONC-392 high, lutetium Lu 1 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal
Phase 1/2 · Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V. AAV9-hSyn1-miGRIK2 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Phase 2 · Eye Cancer, Primary Cancer
AURA Aura Biosciences, Inc. AU-011, SCS Microinjector, Laser ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Phase 2 · Idiopathic Hypersomnia
TAK TAKEDA PHARMACEUTICAL CO LTD TAK-360 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Phase 2 · Narcolepsy Type 2
TAK TAKEDA PHARMACEUTICAL CO LTD TAK-360 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metast
Phase 3 · Breast Cancer
InventisBio Co., Ltd D-0502, Fulvestrant ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12
Phase 1/2 · KRAS G12D Mutation, Advanced Solid Cancer
ARVN ARVINAS, INC. ARV-806 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production C
Phase 2 · Monkeypox (Mpox)
Bavarian Nordic Jynneos, MVA-BN (Quail) ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Pha
Phase 3 · Immune Thrombocytopenia
SNY Sanofi rilzabrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis K
Phase 3 · Osteoarthritis Knee Pain
Saol Therapeutics Inc SL1002, Normal Saline ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Investigating Ovulation Inhibition for Use as a Contraceptive
Phase 2 · Contraception
Mylan Pharmaceuticals Inc MR-130A-01 contraceptive transdermal pat ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE
Phase 2 · Obesity and Cardiovascular Risk
BIOA BioAge Labs, Inc. Oral BGE-102, Oral Placebo Matching BGE- ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-11-30
in 26d
ESTIMATED
READOUT
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemet
Phase 4 · Healthy Volunteers
Karuna Therapeutics, Inc., a Brist KarXT, Trimethobenzamide, Ondansetron, M ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Ly
Phase 2 · Diffuse Large B-cell Lymphoma
KPTI Karyopharm Therapeutics Inc. Selinexor, Selinexor, Selinexor ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Phase 1/2 · Colorectal Cancer, Pancreatic Cancer
Lumicell, Inc. LUM015, LUM 2.6 Imaging Device ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Phase 1/2 · Cancer, Neoplasms
Cancer Vaccines Limited ACIT-1 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patie
Phase 2 · Cushing Syndrome
CORT CORCEPT THERAPEUTICS INC relacorilant ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects Wi
Phase 3 · PAH, Pulmonary Hypertension
UTHR UNITED THERAPEUTICS Corp Ralinepag ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Adva
Phase 3 · Prostatic Neoplasms
Janssen Research & Development, LL Apalutamide, Androgen Deprivation Therap ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stab
Phase 3 · Chronic Stable Angina Pectoris
Tasly Pharmaceuticals, Inc. T89 capsule ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Mus
Phase 2 · Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
TLTFF THERALASE TECHNOLOGIES INC / Ruvidar® (TLD-1433) bladder infusion and ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
Phase 2 · Lumbar Disc Disease
BRTX BioRestorative Therapies, In BRTX-100, Saline ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Phase 1/2 · Metastatic Breast Cancer
Phoenix Molecular Designs PMD-026, fulvestrant ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Exten
Phase 4 · Ulcerative Colitis
BHC Bausch Health Companies Inc. Low Dose Budesonide, High Dose Budesonid ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without
Phase 2/3 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
KPTI Karyopharm Therapeutics Inc. Selinexor (combination therapy), Selinex ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumor
Phase 2 · Solid Tumor
Intra-IMMUSG Pte Ltd PRL3-zumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Phase 1/2 · Glioblastoma, Melanoma Stage IV
Sapience Therapeutics ST101, Temozolomide, Radiation ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation
Phase 1/2 · Dry Age-related Macular Degeneration
Luxa Biotechnology, LLC RPESC-RPE-4W ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Phase 2 · Solid Tumor, Adult, Cancer
EpicentRx, Inc. AdAPT-001, Checkpoint Inhibitor, Immune ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administere
Phase 2/3 · AMD, nAMD
ABBV AbbVie Inc. ABBV-RGX-314, ABBV-RGX-314, Ranibizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Phase 2 · HER2 Positive Metastatic Breast Cancer
Ambrx, Inc. ARX788 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergo
Phase 3 · Congenital Antithrombin Deficiency
Octapharma Atenativ ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Ped
Phase 3 · Primary Immunodeficiency Disease
Kedrion S.p.A. Kedrion IVIG 10% ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castrat
Phase 2 · Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics ZEN003694, Enzalutamide ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Phase 2/3 · Acute Stroke, Ischemic Stroke
DMAC DiaMedica Therapeutics Inc. Recombinant human tissue kallikrein ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Se
Phase 2 · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owne azenosertib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Cap
Phase 2 · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Sunshine Lake Pharma Co., Ltd. HEC585 dose A, HEC585 dose B ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractor
Phase 1/2 · Refractory Metastatic Colorectal Cancer, Solid Tumor
Rottapharm Biotech CR6086, AGEN2034 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyna
Phase 1/2 · Frontotemporal Dementia
DNLI Denali Therapeutics Inc. DNL593 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Phy
Phase 3 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
GNLX GENELUX Corp olvimulogene nanivacirepvec, Platinum ch ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety and Efficacy of APG-157 in Head and Neck Cancer
Phase 2 · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
Aveta Biomics, Inc. APG-157 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due t
Phase 1/2 · Breast Neoplasms, Brain Neoplasms
Stemline Therapeutics, Inc. Elacestrant, Abemaciclib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Proph
Phase 3 · Hereditary Angioedema
IONS IONIS PHARMACEUTICALS INC Donidalorsen ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (i
Phase 2 · Multiple Myeloma
Kite, A Gilead Company anitocabtagene-autoleucel ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Phase 3 · Agitation, Alzheimer's Type Dementia
Suven Life Sciences Limited Masupirdine 50 mg, Masupirdine 100 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K A
Phase 1/2 · HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
SynDevRx, Inc. Evexomostat ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced
Phase 2 · Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
LTRN Lantern Pharma Inc. LP-300, Pemetrexed, Carboplatin ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refra
Phase 1/2 · Lymphoma, B-Cell, Lymphoma, T-Cell
Step Pharma, SAS STP938 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP
Phase 1/2 · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
AP Biosciences Inc. AP203, AP203 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotox
Phase 1/2 · LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma
Dren Bio DR-01 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated
Phase 3 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
RayzeBio, Inc. RYZ101, Everolimus, Sunitinib, Octreotid ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pat
Phase 3 · NASH, Cirrhosis, Liver
MDGL MADRIGAL PHARMACEUTICALS, IN Resmetirom ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of AMDX-2011P in Participants With CAA
Phase 2 · Cerebral Amyloid Angiopathy
Amydis Inc. AMDX-2011P ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fus
Phase 2 · Advanced Cholangiocarcinoma, FGFR2 Fusions
Taiho Oncology, Inc. TAS-120 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in P
Phase 1/2 · Solid Tumor, Adult, Solid Tumor
A2 Biotherapeutics Inc. A2B530, xT-Onco with HLA-LOH Assay ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Phase 2 · Type 1 Diabetes Mellitus With Hypoglycemia
Zucara Therapeutics Inc. ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Ob
Phase 3 · Fecal Incontinence
Cook MyoSite Iltamiocel ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary
Phase 2 · Hypoxic-Ischemic Encephalopathy
ReAlta Life Sciences, Inc. RLS-0071 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Ad
Phase 1/2 · Solid Tumor, Biliary Tract Cancer
TiumBio Co., Ltd. TU2218 + KEYTRUDA® (Pembrolizumab) ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease
Phase 1/2 · Neuronal Ceroid Lipofuscinosis Type 2
Tern Therapeutics, LLC TTX-381, TTX-381 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic
Phase 2 · Lymphatic Malformation
TARA Protara Therapeutics, Inc. TARA-002 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-
Phase 1/2 · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma
BEAM Beam Therapeutics Inc. BEAM-201 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of ALTO-300 in MDD
Phase 2 · Major Depressive Disorder
ANRO Alto Neuroscience, Inc. ALTO-300 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchym
Phase 1/2 · Heart Failure, Systolic
BCDA BioCardia, Inc. CardiALLO™ Human Allogenic Culture-expan ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-a
Phase 3 · Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc Tinengotinib 8 mg, Tinengotinib 10 mg, P ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced o
Phase 2 · Endometrial Cancer, Endometrioid Tumor
Aadi Bioscience, Inc. nab-sirolimus ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
Descartes-08 for Patients With Systemic Lupus Erythematosus
Phase 2 · Systemic Lupus Erythematosus (SLE)
RNAC Cartesian Therapeutics, Inc. Descartes-08 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophi
Phase 2 · Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc. NS-229 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of BN104 in the Treatment of Acute Leukemia
Phase 1/2 · ALL, Adult, AML, Adult
Institut de Recherches Internation BN104 monotherapy, BN104 monotherapy, BN ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squ
Phase 2 · Vulvar Diseases, HPV Infection
Frantz Viral Therapeutics, LLC Artesunate ointment ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Part
Phase 2 · Acute Pancreatitis
Panafina, Inc. RABI-767 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Phase 1/2 · Light Chain (AL) Amyloidosis
Nexcella Inc. NXC-201 CAR-T ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study to Assess Adverse Events and Change in Disease Activity in Previously Trea
Phase 2 · Unresectable Metastatic Colorectal Cancer
ABBV AbbVie Inc. ABBV-400, Bevacizumab, Folinic Acid, Flu ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Phase 1/2 · Arrhythmogenic Cardiomyopathy, PKP2-ACM
LXEO Lexeo Therapeutics, Inc. LX2020 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory
Phase 2/3 · Focal Epilepsy
BHVN Biohaven Ltd. BHV-7000, BHV-7000, BHV-7000 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamic
Phase 1/2 · Solid Tumor
Alyssum Therapeutics AT-1965 Liposome Injection ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patie
Phase 2 · NSCLC
EIKN Eikon Therapeutics, Inc. EIK1001, Pembrolizumab, Paclitaxel, Peme ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate C
Phase 1/2 · MRI Scan
Songqi Gao MT218 injection ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
ZILRETTA in Subjects With Shoulder Osteoarthritis
Phase 3 · Glenohumeral Osteoarthritis
PCRX Pacira BioSciences, Inc. ZILRETTA ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EX
Phase 3 · Pulmonary Arterial Hypertension
Gossamer Bio USA, Inc. Seralutinib, Gereic Dry Powder Inhaler ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumo
Phase 1/2 · Advanced Solid Tumor
Latticon Antibody Therapeutics, In LAT010, LAT010 + ICI ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC)
Phase 2 · Pressure Ulcer, Stage IV, Osteomyelitis
Biocomposites Ltd STIMULAN VG ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal He
Phase 2 · Paroxysmal Nocturnal Hemoglobinuria
OMER OMEROS CORP OMS906 study drug ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Phase 2 Study of WGI-0301 for Advanced HCC
Phase 2 · Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd WGI-0301 at MTD/RP2D dose IV infusion, Q ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
SPI-1005 in Adults Receiving Cochlear Implant
Phase 2 · Hearing Loss, Cochlear Trauma
Sound Pharmaceuticals, Incorporate Ebselen ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalize
Phase 2 · Steroid Refractory GVHD
ReAlta Life Sciences, Inc. RLS-0071 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients W
Phase 3 · Acute Hereditary Angio Edema
Octapharma OCTA-C1-INH ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/2 · Advanced or Metastatic Solid Tumors, Breast Cancer
858 Therapeutics, Inc. ETX-19477 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With o
Phase 2 · Acute Ischemic Stroke
NoNO Inc. NoNO-42 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using
Phase 3 · Binge-Eating Disorder
AXSM Axsome Therapeutics, Inc. Solriamfetol 150 mg, Solriamfetol 300 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia
Phase 2 · Myasthenia Gravis, Myasthenia Gravis, MuSK
NMD Pharma A/S NMD670 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Phase 2 · Basal Cell Carcinoma
Highlight Therapeutics BO-112 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/2 · Melanoma Stage IV, Solid Tumor
Georgiamune Inc GIM-531, Anti-PD-1 monoclonal antibody ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Long-term Safety and Tolerability of BHV-7000
Phase 2 · Focal Epilepsy
BHVN Biohaven Ltd. BHV-7000, BHV-7000 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active
Phase 2 · Moderately to Severely Active Crohn Disease
ABVX Abivax S.A. Obefazimod ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adoles
Phase 3 · Hidradenitis Suppurativa
ABBV AbbVie Inc. Lutikizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Phase 2 · Multifocal Motor Neuropathy
DNTH Dianthus Therapeutics, Inc. Claseprubart ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shif
Phase 3 · Excessive Sleepiness, Shift-work Disorder
AXSM Axsome Therapeutics, Inc. Solriamfetol 150 mg, Solriamfetol 300 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of Eschar
Phase 3 · Venous Leg Ulcer (VLU)
MDWD MediWound Ltd. EscharEx (EX-03) ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone Mas
Phase 2 · Postmenopausal Osteoporosis
Angitia Biopharmaceuticals AGA2118 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or
Phase 1/2 · Solid Tumor
Lamassu Bio Inc SA53-OS (phase 1), SA53-OS (phase 2) ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
Phase 2 · Myopia, Progressive
Sunhawk Vision Biotech, Inc. SHJ002, Atropine ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of
Phase 3 · Eosinophilic Esophagitis
Dr. Falk Pharma GmbH Budesonide ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given D
Phase 2 · Refractory Metastatic Colorectal Cancer
DCTH DELCATH SYSTEMS, INC. Melphalan/HDS Followed by Consolidation ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten R
Phase 1/2 · KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., RNK08954-01 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in A
Phase 3 · Antibody-mediated Rejection
BIIB BIOGEN INC. Felzartamab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Tissue Repair Gel in Venous Leg Ulcers in AU/US
Phase 3 · Venous Leg Ulcer, Venous Ulcer
TR Therapeutics TR987 0.1% gel + Standard of Care ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus
Phase 2/3 · Microvillus Inclusion Disease, Congenital Disorders
Napo Pharmaceuticals, Inc. Crofelemer Powder for Oral Solution ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Phase 2 · Narcolepsy Type 1, Narcolepsy Type 2
Centessa Pharmaceuticals (UK) Limi ORX750 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Wit
Phase 1/2 · Type 1 Diabetes Mellitus, T1D
COUR Pharmaceutical Development Co CNP-103 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent
Phase 3 · Pneumococcal Infections
SNY Sanofi PCV21, 20vPCV ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
Spermatogonial Differentiation Via Testicular Organoid
Phase 1/2 · Infertility, Male, Gene Abnormality
CellARTs Inc. Stem cell, Genetic Screening, Genetic Re ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of Navenibart in Participants With Hereditary Angioedema
Phase 3 · Hereditary Angioedema (HAE)
Astria Therapeutics, Inc. navenibart ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced
Phase 2 · Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy
DWTX Dogwood Therapeutics, Inc. Halneuron, Halneuron (Open Label Extensi ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the
Phase 1/2 · oGHVD
Regenerative Ocular Immunobiologic d-MAPPS, PI and Patient Masked ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Phase 3 · Meniere's Disease, Ménière's Disease
Sound Pharmaceuticals, Incorporate Ebselen ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Struc
Phase 1/2 · Pandemic Influenza Immunization, Healthy Volunteers
SNY Sanofi Pandemic flu H5 HA mRNA SD2 vaccine ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retini
Phase 2 · Retinitis Pigmentosa
jCyte, Inc human retinal progenitor cells, Mock inj ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety and Efficacy of VDPHL01 in Males With AGA
Phase 3 · Androgenetic Alopecia, AGA
MANE Veradermics, Inc VDPHL01 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic
Phase 1/2 · Neurotrophic Keratitis
KRYS Krystal Biotech, Inc. KB801 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerabil
Phase 3 · Developmental and Epileptic Encephalopathy 1
PRAX Praxis Precision Medicines, 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermo
Phase 3 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
KRYS Krystal Biotech, Inc. KB803 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Saf
Phase 3 · Epileptic Encephalopathy, SCN2A Encephalopathy
PRAX Praxis Precision Medicines, 1mg elsunersen, 0.5mg elsunersen ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Sy
Phase 2 · Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc. Ninerafaxstat 200mg MR ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With
Phase 3 · Chronic Primary Immune Thrombocytopenia (ITP)
Kedrion S.p.A. Kedrion IVIG 10% ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemoli
Phase 2 · Chronic Pruritus of Unknown Origin
Galderma R&D nemolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infect
Phase 3 · Viral Hepatitis
VIR Vir Biotechnology, Inc. Tobevibart, Elebsiran, Bulevirtide ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (
Phase 1/2 · Parkinson's Disease (PD)
EicOsis Human Health Inc. EC5026 oral tablet ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by
Phase 2 · Nausea, Vomiting
LLY ELI LILLY & Co LY3537021, Background Chemotherapy ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifung
Phase 2 · Invasive Mould Infection
Elion Therapeutics, Inc. EL219, Active Comparator- IV Antifungal ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment
Phase 3 · Social Anxiety Disorder (SAD)
VNDA Vanda Pharmaceuticals Inc. VQW-765 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With
Phase 2 · Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
Ventus Therapeutics U.S., Inc. VENT-03 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2 · Atopic Dermatitis (AD)
Enveda Therapeutics ENV-294 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
Phase 2 · Asthma
Enveda Therapeutics ENV-294 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Phase 2 · Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Pulmovant, Inc. inhaled mosliciguat, Dry Powder Inhaler ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Phase 3 · Primary Vitreoretinal Lymphoma
ALDX Aldeyra Therapeutics, Inc. ICM ADX-2191 injection, Monthly ADX-2191 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-01
in 27d
ESTIMATED
READOUT
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1
Phase 3 · Nausea and Vomiting, Obesity
VNDA Vanda Pharmaceuticals Inc. Tradipitant ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Partici
Phase 2 · RSV Infection, RSV
ENTA ENANTA PHARMACEUTICALS INC zelicapavir ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Canc
Phase 3 · Lung Cancer, Lung Metastases
Vergent Bioscience, Inc. Abenacianine, Near Infrared (NIR) Imagin ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospit
Phase 2 · Hypertension, Acute Severe Hypertension
KARD Kardigan, Inc. Tonlamarsen ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL
Phase 1/2 · Bipolar I Disorder
ALZN Alzamend Neuro, Inc. AL001, Lithium carbonate ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
Phase 2/3 · Dry Eye Disease (DED)
OCS Oculis Holding AG Artificial Tear Run-in, licaminlimab, Ve ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
Rademikibart IV for Acute Asthma and COPD Exacerbation
Phase 2 · Asthma Acute, COPD Exacerbation Acute
Connect Biopharm LLC Rademikibart ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12 (month)
in 27d
ESTIMATED
READOUT
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Sus
Phase 3 · Postoperative Ocular Inflammation, Postoperative Ocular Pain
HROW HARROW, INC. TRIESENCE (triamcinolone acetonide injec ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-02
in 28d
ESTIMATED
READOUT
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 t
Phase 3 · Severe Alopecia Areata
PFE PFIZER INC Ritlecitinib higher dose, Ritlecitinib l ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-03
in 29d
ESTIMATED
READOUT
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999,
Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT)
REGN REGENERON PHARMACEUTICALS, I REGN7999 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-03
in 29d
ESTIMATED
READOUT
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early
Phase 2 · Alzheimer's Disease
Eisai Inc. E2814, Lecanemab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-04
in 30d
ESTIMATED
READOUT
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D
Phase 3 · Lyme Disease
PFE PFIZER INC VLA15 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-08
in 1mo
ESTIMATED
READOUT
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Phase 3 · Atrial Fibrillation
Janssen Research & Development, LL Milvexian, Apixaban, Apixaban Placebo ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-08
in 1mo
ESTIMATED
READOUT
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults
Phase 2 · Hidradenitis Suppurativa
PFE PFIZER INC Ritlecitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-09
in 1mo
ESTIMATED
READOUT
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As
Phase 3 · Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Brist KarXT ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-10
in 1mo
ESTIMATED
READOUT
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People Wi
Phase 3 · Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim zongertinib, pembrolizumab, cisplatin, c ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-10
in 1mo
ESTIMATED
READOUT
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Ba
Phase 2 · Chronic Kidney Disease and Hypertension
AZN ASTRAZENECA PLC Baxdrostat/dapagliflozin, Baxdrostat/Pla ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-11
in 1mo
ESTIMATED
READOUT
Extended Access of Momelotinib in Adults With Myelofibrosis
Phase 2 · Primary Myelofibrosis
GlaxoSmithKline Momelotinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-11
in 1mo
ESTIMATED
READOUT
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th
Phase 2 · Urothelial Carcinoma
Seagen, a wholly owned subsidiary disitamab vedotin, pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-11
in 1mo
ESTIMATED
READOUT
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-co
Phase 4 · SARS-CoV-2
ModernaTX, Inc. mRNA-1273, mRNA-1283 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-14
in 1mo
ESTIMATED
READOUT
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moder
Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NVS NOVARTIS AG AAA617, 68Ga-PSMA-11 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-14
in 1mo
ESTIMATED
READOUT
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in
Phase 2 · Heart Failure
BMY BRISTOL MYERS SQUIBB CO BMS-986435 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-14
in 1mo
ESTIMATED
READOUT
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Phase 3 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
AMGN AMGEN INC ABP 234, Pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-14
in 1mo
ESTIMATED
READOUT
A Study on the Immune Response and Safety of the Second Dose of an Investigation
Phase 3 · Chickenpox
GlaxoSmithKline Investigational varicella vaccine, Marke ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-14
in 1mo
ESTIMATED
READOUT
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20
Phase 2 · Palmoplantar Pustulosis
LEO Pharma Delgocitinib cream, Vehicle cream ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-14
in 1mo
ESTIMATED
READOUT
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help P
Phase 2 · Overweight, Obesity
NVO NOVO NORDISK A S NNC0662-0419 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (
Phase 3 · Schizophrenia
Gedeon Richter Plc. Cariprazine ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5
Phase 1/2 · Advanced Solid Tumor, Advanced Malignant Neoplasm
PMVP PMV Pharmaceuticals, Inc. rezatapopt, pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory De
Phase 2/3 · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LL Nipocalimab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab
Phase 1/2 · Solid Tumor, Adult, Refractory Cancer
GV20 Therapeutics GV20-0251, GV20-0251, GV20-0251 and Pemb ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic
Phase 3 · Non-Clear Cell Renal Cell Carcinoma
EXEL EXELIXIS, INC. XL092, Nivolumab, Sunitinib Malate ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With ACh
Phase 3 · Generalized Myasthenia Gravis, gMG
Alexion Pharmaceuticals, Inc. Gefurulimab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Ad
Phase 2 · Locally Advanced Pancreatic Adenocarcinoma
EXACT Therapeutics AS Acoustic Cluster Therapy, Modified FOLFI ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Modera
Phase 3 · Moderate to Severe Glabellar Lines
Ipsen Corabotase ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-15
in 1mo
ESTIMATED
READOUT
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults W
Phase 3 · Moderate to Severe Glabellar Lines
Ipsen Corabotase ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-16
in 1mo
ESTIMATED
READOUT
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodyn
Phase 3 · NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Hoffmann-La Roche Satralizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-16
in 1mo
ESTIMATED
READOUT
A Clinical Investigation of a Topical Moisturizer on Skin Barrier Function in Ad
Phase 4 · Sensitive Skin
Good Molecules, LLC White petrolatum, Investigational moistu ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-17
in 1mo
ESTIMATED
READOUT
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Mon
Phase 2 · Alzheimer Disease, Early Onset
BMY BRISTOL MYERS SQUIBB CO BMS-986446 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-17
in 1mo
ESTIMATED
READOUT
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Cr
Phase 2 · Crohn's Disease
SNY Sanofi brivekimig ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-17
in 1mo
ESTIMATED
READOUT
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participan
Phase 2 · Ulcerative Colitis
SNY Sanofi SAR442970 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-17
in 1mo
ESTIMATED
READOUT
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
TAK TAKEDA PHARMACEUTICAL CO LTD TAK-861 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-18
in 1mo
ESTIMATED
READOUT
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymo
Phase 2/3 · Breast Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponso Raloxifene - Usual, Raloxifene - Study ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-18
in 1mo
ESTIMATED
READOUT
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polym
Phase 2/3 · SCLC
Han Xu, M.D., Ph.D., FAPCR, Medica Topotecan - usual, Topotecan - study ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-21
in 2mo
ESTIMATED
READOUT
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and
Phase 3 · Hidradenitis Suppurativa
UCB Biopharma SRL Bimekizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-22
in 2mo
ESTIMATED
READOUT
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa
Phase 1/2 · Renal Cell Carcinoma
Merck Sharp & Dohme LLC Belzutifan, Palbociclib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-22
in 2mo
ESTIMATED
READOUT
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
Phase 2 · Alzheimer Disease
Janssen Pharmaceutica N.V., Belgiu JNJ-64042056 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-22
in 2mo
ESTIMATED
READOUT
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of
Phase 2 · Geographic Atrophy
Boehringer Ingelheim BI 1584862 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-22
in 2mo
ESTIMATED
READOUT
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants
Phase 3 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Adverum Biotechnologies, Inc. Ixo-vec, Aflibercept ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-23
in 2mo
ESTIMATED
READOUT
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Tim
Phase 3 · Asthma
AZN ASTRAZENECA PLC Benralizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-23
in 2mo
ESTIMATED
READOUT
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients
Phase 2 · Prostatic Neoplasm
NVS NOVARTIS AG AAA617, AAA517, Piflufolastat F 18, ARPI ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-23
in 2mo
ESTIMATED
READOUT
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With
Phase 1/2 · Non-Hodgkin Lymphoma
Cho Pharma Inc. CHO-H01, CHO-H01 at RP2D, Lenalidomide ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-23
in 2mo
ESTIMATED
READOUT
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-
Phase 2 · Metastatic Castration-resistant Prostate Cancer
Fusion Pharmaceuticals Inc. FPI-2265 ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-23
in 2mo
ESTIMATED
READOUT
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab
Phase 2 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
SNY Sanofi frexalimab, brivekimig, rilzabrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-25
in 2mo
ESTIMATED
READOUT
A Study on the Immune Response and Safety of an Investigational Chickenpox Vacci
Phase 3 · Chickenpox
GlaxoSmithKline Investigational varicella vaccine_Lot 1, ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-25
in 2mo
ESTIMATED
READOUT
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont
Phase 2 · Chronic Spontaneous Urticaria
PFE PFIZER INC Ritlecitinib 50 mg, Ritlecitinib 100 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-26
in 2mo
ESTIMATED
READOUT
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovari
Phase 3 · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
CanariaBio Inc. Oregovomab, Paclitaxel, Carboplatin, Car ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-26
in 2mo
ESTIMATED
READOUT
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Partici
Phase 3 · Hidradenitis Suppurativa (HS)
INCY INCYTE CORP Povorcitinib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-27
in 2mo
ESTIMATED
READOUT
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Vari
Phase 1/2 · Breast Cancer, Metastatic Breast Cancer
Stemline Therapeutics, Inc. Elacestrant, Alpelisib, Everolimus, Ribo ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-27
in 2mo
ESTIMATED
READOUT
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution
Phase 2 · Dry Eye Disease (DED)
Dompé Farmaceutici S.p.A DFL24498, Vehicle ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-27
in 2mo
ESTIMATED
READOUT
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients Wit
Phase 2 · High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion
Amplexd Therapeutics, Inc. EGCG and Quinine Sulfate Vaginal Supposi ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-28
in 2mo
ESTIMATED
READOUT
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed
Phase 2 · Ovarian Neoplasms, Breast Neoplasms
GlaxoSmithKline Niraparib ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-28
in 2mo
ESTIMATED
READOUT
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-a
Phase 2 · Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition
Frantz Viral Therapeutics, LLC Artesunate ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-29
in 2mo
ESTIMATED
READOUT
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult P
Phase 2 · Hypercholesterolemia
REGN REGENERON PHARMACEUTICALS, I Alirocumab ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-30
in 2mo
ESTIMATED
READOUT
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients
Phase 3 · Tuberous Sclerosis Complex
NVS NOVARTIS AG everolimus ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-30
in 2mo
ESTIMATED
READOUT
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Phase 2 · Hepatocellular Carcinoma, Gastric Cancer
Teclison Ltd. Nivolumab Injectable Product, Trans-arte ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
2026-12-30
in 2mo
ESTIMATED
READOUT
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanc
Phase 3 · Renal Cell Carcinoma
Xynomic Pharmaceuticals, Inc. Pazopanib, Abexinostat ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.